Table 3. Model validation and comparison with regard to identifying BAV patients in the validation group.
| Metabolomic target | Cutoffs | Patients classified N (%) | Diagnostic accuracy | AUC | |
|---|---|---|---|---|---|
| MG (18:2) | 237.9 | 28 (56) | Sen (%) | 76.7 | 0.815 |
| Spe (%) | 85.0 | ||||
| PPV (%) | 80.0 | ||||
| NPV (%) | 80.0 | ||||
| Glycerophospho-N-Oleoyl Ethanolamine | 277.56 | 30 (60) | Sen (%) | 76.7 | 0.793 |
| Spe (%) | 70.0 | ||||
| PPV (%) | 76.7 | ||||
| NPV (%) | 65.0 | ||||
| PE (18:2) | 1447.81 | 35 (70) | Sen (%) | 73.3 | 0.738 |
| Spe (%) | 75.0 | ||||
| PPV (%) | 83.3 | ||||
| NPV (%) | 50.0 | ||||
| ZS | −0.1634 | 27 (54) | Sen (%) | 76.7 | 0.93 |
| Spe (%) | 90.0 | ||||
| PPV (%) | 80.0 | ||||
| NPV (%) | 85.0 | ||||
Sen = sensitivity; Spe = specificity; PPV = positive predictive value; NPV = negative predictive value.